尋常性天疱瘡治療の世界市場：2024-2031年

概要

世界の尋常性天疱瘡治療市場は、2023年に4億7,340万米ドルに達し、2024年から2031年にかけてCAGR 8.3％で成長し、2031年には8億9,610万米ドルに達すると予測されています。

尋常性天疱瘡はまれな自己免疫疾患群です。全身の皮膚や粘膜に水疱を生じます。口、鼻、のど、目、生殖器に影響を及ぼすこともあります。天疱瘡の最も一般的なタイプとして、その発症は一般的に40～60歳の間に起こり、男女ともに同様に罹患します。非常に重篤ですが、治療によってコントロールすることができます。

尋常性天疱瘡治療のために市販されている主な治療法は、ステロイド錠やazathioprine、methotrexate、rituximabなどの医薬品です。全身的なコルチコステロイド療法も治療の1つであり、重症度や患者、併存する可能性のある疾患に応じて、プレドニゾロン換算で1.0～1.5mg/kg/日の投与が推奨されます。尋常性天疱瘡治療のために市場で入手可能な新しい治療法には、veltuzumab、ocrelizumab、obinutuzumabなどがあります。

市場力学：

促進要因

尋常性天疱瘡の罹患率および有病率の増加

世界の静脈ファインダーの需要は複数の要因によって牽引されています。主な要因の1つは、尋常性天疱瘡の罹患率と有病率の増加です。

尋常性天疱瘡は、皮膚や粘膜に重度の水疱形成を引き起こす、まれで生命を脅かす可能性のある自己免疫疾患です。2023年8月にNCBIが発表した調査によると、尋常性天疱瘡の罹患率は人口10万人あたり0.098～5人でした。PVの有病率は人口10万人当たり0.38～30人でした。

さらに、業界の主要企業は尋常性天疱瘡の治療に注力しており、臨床試験の増加、革新的な製品の上市および承認がこの市場の成長を促進するであろう。例えば、2023年5月、Topas社はセリアック病治療の第IIa相試験を開始しました。プラセボ対照、二重盲検、無作為化、多施設共同試験で、用量漸増コホートにおける2回のTPM502投与の忍容性、安全性、薬力学的効果を評価します。この第Ⅱa相試験は、尋常性天疱瘡治療患者を対象としたTPM203の第Ⅰ相試験で得られた良好な臨床データに基づいて開始されました。

同様に、2022年7月、Almirallは皮膚疾患に対する革新的な治療法を見出すための新たな募集を開始しました。皮膚科学研究における共同研究を確立するための提案のためのオープンイノベーションプラットフォームです。今回は、皮膚疾患の新たな治療法となりうる前臨床または臨床開発段階にあるアセットについて、新たなパートナーシップの機会を見出すことを目的としています。

抑制要因

高額な治療費、投薬に伴う副作用、厳しい規制ガイドライン、認知度・診断不足などの要因が市場の妨げになると予想されます。

目次

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 尋常性天疱瘡の発生率と有病率の増加
    • 自己免疫疾患の治療の進歩
  • 抑制要因
    • 高い治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 治療タイプ別

• 副腎皮質ステロイド薬
• 免疫抑制剤
• 生物学的療法
• 免疫グロブリン静注（IVIG）療法
• その他

第7章 投与経路別

• 経口
• 非経口
• 皮下

第8章 エンドユーザー別

• 病院・クリニック
• 皮膚科専門クリニック
• 研究・学術研究所

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• F. Hoffmann-La Roche Ltd.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Pfizer Inc
• Teva Pharmaceutical Industries
• Novartis AG
• Sanofi
• AbbVie Inc
• AstraZeneca
• Zydus Group
• GSK Plc
• Syntimmune

第12章 付録

Overview

The global pemphigus vulgaris treatment market reached US$ 473.4 million in 2023 and is expected to reach US$ 896.1 million by 2031 growing with a CAGR of 8.3% during the forecast period 2024-2031.

Pemphigus vulgaris is a rare group of autoimmune diseases. It causes blisters on the skin and mucous membranes throughout the body. It can affect the mouth, nose, throat, eyes, and genitals. As the most prevalent type of pemphigus, its onset typically occurs between ages 40 and 60, affecting both genders equally. It can be very serious, but treatment can help to control it.

The main treatments available in the market for treating pemphigus vulgaris treatment are steroid tablets and other medicines such as azathioprine, methotrexate, and rituximab. Systemic corticosteroid therapy is another form of treatment and is recommended at a dose of 1.0-1.5 mg/kg/day of prednisolone equivalent, depending on disease severity, the patient a possible comorbidities. Some of the new treatments available in the market for the treatment of pemphigus vulgaris treatment are veltuzumab, ocrelizumab, and obinutuzumab.

Market Dynamics: Drivers

Increasing incidence and prevalence of pemphigus vulgaris disease

The demand for the global vein finders market is driven by multiple factors. One of the primary factors is the increasing incidence and prevalence of pemphigus vulgaris disease.

Pemphigus vulgaris is a rare and potentially life-threatening autoimmune disorder that causes severe blistering of the skin and mucous membranes. According to an NCBI research publication in August 2023, the incidence of PV ranged from 0.098 to 5 patients per 100,000 people. The prevalence of PV ranged from 0.38 to 30 per 100,000 people.

Moreover, key players in the industry focus on the treatment for pemphigus vulgaris, and the rising number of clinical trials, innovative product launches, & approvals would drive this market growth. For instance, in May 2023, Topas launched the Phase IIa trial of celiac disease therapy. The placebo-controlled, double-blind, randomized, multicenter study will assess the tolerability, safety, and pharmacodynamic effects of two TPM502 administrations in dose-escalating cohorts. The Phase IIa study has been launched based on the positive clinical data from the Phase I study of TPM203 in pemphigus vulgaris treatment patients.

Similarly, in July 2022, Almirall launched a new call to find innovative therapies for skin diseases. An open innovation platform for proposals to establish collaborations in dermatological research. This year's edition aims to find new partnership opportunities for assets in preclinical or clinical development stages that can become new treatments for skin diseases.

Restraints

Factors such as the high cost of treatment, adverse effects associated with the medication, stringent regulatory guidelines, and lack of awareness & Diagnosis are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global pemphigus vulgaris treatment is segmented based on treatment type, route of administration, end-user, and region.

The biological therapies segment accounted for approximately 43.3% of the global pemphigus vulgaris treatment share

The biological therapies segment is expected to hold the largest market share over the forecast period owing to biologics excelling in treating pemphigus vulgaris treatment due to their targeted effectiveness, addressing disease-related molecules precisely. With minimal side effects, they surpass traditional therapies. Cost-wise, biologics prove economical, utilizing living cells or natural sources, and reducing production and distribution expenses.

Moreover, their lower dosage requirement further cuts treatment costs. Individualized treatment is another advantage, as biologics can be tailored to target specific molecules, enhancing efficacy. Advancements in both disease understanding and biotechnology have yielded advanced biologics, solidifying their status as the favored choice for pemphigus vulgaris treatment furthermore, the rise in European approvals.

According to Dovepress research publication in October 2022, anti-CD20 monoclonal antibody rituximab is an approved adjuvant treatment, in combination with oral corticosteroids, for patients with pemphigus vulgaris, a severe and potentially life-threatening autoimmune blistering skin disorder. Updated approaches to the management of pemphigus vulgaris support rituximab as a first-line adjuvant treatment to induce remission early in the course of the disease.

Similarly, in Frontiers' publication in February 2022, biological thiol substances such as cysteine and glutathione have been shown to induce acantholysis in human skin fragments under certain experimental conditions. In vitro experiments subsequently demonstrated that thiol drugs (d-penicillamine, captopril, theobromine, and piroxicam) induce acantholytic splitting in human skin fragments or skin cultures in the absence of pemphigus antibodies.

From the same source, more recently, advances in our understanding of the pathogenesis of pemphigus and the biological mechanisms of therapeutics have led to a paradigm shift in the treatment of this disease, from blanket immunosuppression towards a more targeted restriction of autoimmunity.

Moreover, the rising number of clinical trials would propel this segment's growth. For instance, In January 2023, Dr Reddy completed clinical studies of its rituximab biosimilar for filing in the US, and Europe.

The full set of clinical studies of Dr Reddy's Laboratories Ltd (Dr Reddy's) pro. According to the company, DRL_RI is being developed as a biosimilar of rituximab, a cluster of differentiation 20 (CD20) directed cytolytic antibodies for approval. Including treatment of adult patients with pemphigus vulgaris treatment and other autoimmune disorders.

Geographical Analysis

North America accounted for approximately 41.2% of the global pemphigus vulgaris market share

North America region is expected to hold the largest market share over the forecast period owing to the increasing incidence & prevalence of pemphigus vulgaris, well-advanced healthcare infrastructure, and rising awareness among individuals would propel this market growth in this region.

Pemphigus vulgaris (PV) is a rare autoimmune disorder of the skin and mucous membranes that causes painful sores and blisters on the skin and mouth. According to PAN Foundation in January 2023, about three in every 100,000 people in the U.S. are living with pemphigus vulgaris. Every year, PV incidence varies from 0.1-0.5 cases per 100,000 population with a higher prevalence in Europe and the United States of America.

Moreover, government initiatives such as financial support and key strategies such as partnerships & collaborations would drive this market growth in this region. For instance, in January 2023, the PAN Foundation opened a new financial assistance program for people living with pemphigus vulgaris, providing up to $6,600 per year for eligible patients.

We are proud to launch this new fund, offering support to those affected by this rare and chronic disease. Pemphigus vulgaris can be life-threatening if left untreated, and we hope that PAN's financial support will make sure more people will be able to access the care they need.

Also, in August 2023, Cabaletta Bio and WuXi Advanced Therapies announced the expansion of the GMP Manufacturing agreement to include CABA-201. One of the strategies is the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis.

Market Segmentation

By Treatment Type

• Corticosteroid
• Immunosuppressants
• Biological Therapies
• Intravenous Immunoglobulin (IVIG) Therapy
• Others

By Route of Administration

• Oral
• Parenteral
• Subcutaneous

By End User

• Hospitals & Clinics
• Specialty Dermatology Clinics
• Research & Academic Laboratories

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the pemphigus vulgaris treatment market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Teva Pharmaceutical Industries, Novartis AG, Sanofi, AbbVie Inc, AstraZeneca, Zydus Group, GSK Plc and Syntimmune among others.

Key Developments

• In December 2023, argenx SE announced topline results from the address study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and pemphigus foliaceus (PF).
• In October 2022, IASO Biotherapeutics announced that the companies entered into an agreement under which Cabaletta obtained from IASO Bio an exclusive, worldwide license to develop, manufacture, and commercialize a clinically validated fully human CD19 binder for use in a product that is designed to modify T cells in the treatment of autoimmune diseases.

Why Purchase the Report?

• To visualize the global pemphigus vulgaris treatment market segmentation based on treatment type, route of administration, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of pemphigus vulgaris treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global pemphigus vulgaris treatment market report would provide approximately 62 tables, 58 figures, and 182 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Treatment Type
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by End User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Incidence and Prevalence of Pemphigus Vulgaris Disease
    • 4.1.1.2. Advancements in the Treatment of Autoimmune Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Treatment Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 6.1.2. Market Attractiveness Index, By Treatment Type
• 6.2. Corticosteroid
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Immunosuppressants
• 6.4. Biological Therapies
• 6.5. Intravenous Immunoglobulin (IVIG) Therapy
• 6.6. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, Route of Administration
• 7.2. Oral *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral
• 7.4. Subcutaneous

8. By End User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 8.1.2. Market Attractiveness Index, By End User
• 8.2. Hospitals & Clinics *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Dermatology Clinics
• 8.4. Research & Academic Laboratories

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. F. Hoffmann-La Roche Ltd.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Pfizer Inc
• 11.3. Teva Pharmaceutical Industries
• 11.4. Novartis AG
• 11.5. Sanofi
• 11.6. AbbVie Inc
• 11.7. AstraZeneca
• 11.8. Zydus Group
• 11.9. GSK Plc
• 11.10. Syntimmune

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us